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This article presents the guidelines on Beta-thalassemia
major – regular blood transfusion therapy.
Description  of  the  method  used  to  gatheratão Roxo, 2501, Monte Alegre, 14051-140 Ribeirão Preto, SP, Brazil.
These guidelines use the technique of systematic review and
information recovery based on the evidence-based medicine
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
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movement, in which clinical experience is integrated with
the possibility to critically analyze and rationally apply sci-
entiﬁc information thereby improving the quality of medical
care. Evidence-based medicine uses existing scientiﬁc evi-
dence with good internal and external validity in the clinical
practice.1,2
Today, systematic reviews are considered the highest level
of evidence for any clinical question as they systematically
summarize information on a particular topic using a repro-
ducible methodology to analyze primary studies (clinical
trials, cohort, case–control or cross-sectional studies), as well
as integrating information on efﬁciency, effectiveness and
safety.1,2
The questions of these guidelines were structured using
the Patient/Problem, Intervention, Comparison and Outcome
(PICO) system, allowing the generation of evidence search
strategies in the key scientiﬁc databases (Annex I).1,2
Degree  of  recommendation  and  level  of
evidence
A: Major experimental and observational studies
B: Minor experimental and observational studies
C: Case reports (non-controlled studies)
D: Opinion without critical evaluation based on consensus,
physiological studies or animal models
Background
Beta-thalassemia syndromes are a group of inherited disor-
ders characterized by a genetic deﬁciency in the synthesis of
beta globin chains.
Beta-thalassemia affects one or both of the beta-globin
genes (chromosome 11). These point or, more  rarely, dele-
tion mutations cause improper synthesis of beta-globin, a
component of hemoglobin, resulting in anemia.3,4 It is inher-
ited as an autosomal recessive disease; however dominant
mutations have also been reported. The defect may be a
complete lack of the beta-globin protein (i.e. 0-thalassemia)
or greatly reduced synthesis of beta-globin protein (i.e. +-
thalassemia).5 There is a decrease of approximately 50% in
the synthesis of beta-globin protein in the heterozygous state,
that is, beta-thalassemia minor or beta-thalassemia trait
which causes mild to moderate microcytic anemia. In beta-
thalassemia major (i.e. homozygous beta-thalassemia), the
production of beta-globin chains is greatly impaired because
both beta globin genes are mutated. The intense imbalance
of globin chain synthesis (alpha  beta) results in ineffective
erythropoiesis and severe hypochromic microcytic anemia.6
There is also the intermediate form of beta-thalassemia (beta-
thalassemia intermedia), in which mutations of both beta
genes occur (a mild mutation in one and a severe mutation
in the other, or two mild mutations or a complex muta-
tion that may be associated with alpha thalassemia). In this
condition, patients can have from mild anemia to anemia
requiring red blood cell transfusions, sometimes similar to
beta-thalassemia major.7 2 0 1 6;3  8(4):341–345
Additional factors inﬂuence the clinical manifestations
of the disease, i.e., the same mutations may have different
clinical manifestations in different patients. The follow-
ing factors are known to inﬂuence the clinical phenotype:
intracellular fetal hemoglobin concentrations, co-inheritance
with alpha thalassemia and coexistence with sickle cell
trait.6
Treatment of patients with beta-thalassemia major
includes chronic transfusion therapy, iron chelation, splenec-
tomy, allogeneic hematopoietic stem cell transplantation
and support measures. Regular transfusion therapy leads to
complications related to iron overload, including endocrine
manifestations (delayed growth, impaired sexual maturation,
diabetes mellitus and parathyroid, thyroid, pituitary and, less
commonly, adrenal insufﬁciency), dilated cardiomyopathy,
liver ﬁbrosis and cirrhosis.4,6
Objective
The purpose of these guidelines is to provide recommenda-
tions that can assist in decision making about the therapeutic
role and regimen of blood transfusions in patients with beta-
thalassemia major.
What  is  the  purpose  and  recommended
regimen  of  transfusions  in  the  treatment  of
beta-thalassemia  major?
The objectives of transfusion therapy is to correct ane-
mia, suppress erythropoiesis and inhibit gastrointestinal iron
absorption that occurs in untransfused patients as a result of
increased, albeit ineffective, erythropoiesis.
The decision to start transfusion therapy in patients with
conﬁrmed diagnosis of beta-thalassemia should be based on
the presence of severe anemia with hemoglobin (Hb) lev-
els < 7 g/dL on two occasions at an interval of more  than
two weeks. All other possible contributing factors such as
infections, folic acid deﬁciency, coinheritance of glucose-6-
phosphate dehydrogenase (G6PD) deﬁciency and blood loss
must be discarded. However, any of the following clinical crite-
ria, regardless of the Hb level (>7 g/dL) should be considered:
facial changes, poor growth, spontaneous fractures and clini-
cally signiﬁcant extramedullary hematopoiesis. The need for
transfusions can start as early as six months old.5 (D)  When
possible, the decision to start regular transfusions should not
be delayed until after the second to third year of life, due
to the risk of developing several anti-red blood cell antibod-
ies and subsequent difﬁculty in ﬁnding compatible units for
transfusion.7–10 (D) (B)
The recommended treatment for beta-thalassemia
major involves regular red blood cell transfusions through-
out life, usually administered every two to ﬁve weeks
depending on the transfusion needs of each individual in
order to maintain the pre-transfusion level of hemoglobin
between 9 and 10.5 g/dL.5,8 (D) This transfusion regimen
promotes proper growth, allows normal physical activ-
ities, adequately inhibits bone marrow activity in most
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atients and minimizes the accumulation of transfusional
ron.11,12 (B)
A pre-transfusion hemoglobin level between 11 and 12 g/dL
ay be appropriate for patients with heart disease, clinically
igniﬁcant extramedullary hematopoiesis and splenomegaly.
xtramedullary hematopoiesis occurs in patients who do not
chieve adequate suppression of bone marrow activity with
ower hemoglobin levels. Some patients with lower back pain
ear the time of transfusion may need to maintain higher pre-
ransfusion Hb levels too.8 (D)
The mean target Hb should be 12 g/dL. Post-transfusion
emoglobin should be maintained at a maximum between
4 and 15 g/dL, because the higher the post-transfusion Hb
evel the greater the hyperviscosity which increases the risk
f stroke.8 (D)
Patients starting regular transfusion regimens should be
accinated against hepatitis A and B (depending on the age)
nd their cytomegalovirus status should be assessed.3 (D)
The development of one or more  speciﬁc anti-red blood cell
ntibodies (alloimmunization) is an important complication of
egular transfusion therapy.13–15 (B)
Before starting transfusion therapy, the patient’s blood type
ust be determined as well as red blood cell phenotyping for
t least the C, c, D, E, e, and Kell antigens in order to help
dentify and characterize antibodies in the case of subsequent
mmunization. Preferably, extended phenotyping should be
ade including antigens of other blood systems such as Duffy
nd Kidd and genotyping.8 (D)
Baseline phenotyping and genotyping is important to mon-
tor patients carefully for the development of new antibodies
nd to avoid the transfusion of packed red blood cell units with
he corresponding antigens.8 (D)
The use of packed washed leukocyte depleted/ﬁltered
ed blood cells is recommended for all patients to reduce
llergic reactions and febrile non-hemolytic transfusion
eactions, as well as cytomegalovirus infection.3 (D) The
ashing of packed red blood cells is in fact indicated for
atients with repeated allergic reactions and IgA-deﬁcient
atients.8 (D)
The amount of red blood cells to be transfused depends
n several factors, such as patient weight, target Hb level
nd hematocrit of the blood bag. In clinically stable patients,
pproximately 8–15 mL/kg body weight of red blood cells can
e infused over a period of 1–2 h.3 (D)
Authors suggest that current recommendations lead to
nder-transfusion in men. As a result, they may be more
ikely to have extramedullary hematopoiesis and thus more
ikely to require splenectomy or develop spinal cord com-
ression, a rare, but serious complication of paravertebral
xtramedullary hematopoiesis. In a study of 116 patients
51 men  and 65 women) with beta-thalassemia major, men
eceived more  packed red blood cell units per transfusion
nd had a higher annual transfusion volume. However,
ith the correction for weight, the women received a
reater transfused volume per kg: 225 mL/kg in women
ersus 202 mL/kg in men  (p-value = 0.028). Erythropoietin lev-
ls (EPO) were higher in men  (72 mIU/mL) compared to
omen (52 mIU/mL; p-value = 0.006). The incidence of splenec-
omy was also higher in men  (61% versus 40% in women;
-value = 0.031).15 (B) 1 6;3  8(4):341–345 343
The need for transfusion in non-splenectomized patients is
generally higher (approximately 30%) than in splenectomized
patients.16 (B)
Recommendations
In patients with beta-thalassemia major:
- Patients starting regular transfusion regimens should
be vaccinated against hepatitis A and B (depending on
the age) and their cytomegalovirus status should be
assessed.
- Before starting transfusion therapy, the patient’s blood
type must be determined as well as red blood cell phen-
otyping for at least the C, c, D, E, e, and Kell antigens
in order to help identify and characterize antibodies
in the case of subsequent immunization. Preferably,
extended phenotyping should be made including anti-
gens of other blood systems such as Duffy and Kidd
and genotyping.
- Patients should be monitored for the development of
new antibodies to avoid the transfusion of red blood
cell units with the corresponding antigens.
- The use of packed washed leukocyte depleted/ﬁltered
red blood cells is recommended for all patients. The
washing of red blood cells is indicated for patients at
risk of allergic reactions.
- Transfuse every 2–5 weeks, maintaining the pre-
transfusion hemoglobin level from 9–10.5 g/dL or
higher (11–12 g/dL) for patients with cardiac complica-
tions. Keep post-transfusion hemoglobin levels below
15 g/dL.
- Approximately 8–15 mL/kg body weight of packed red
blood cells can be infused over a period of 1–2 h in clin-
ically stable patients.
- The need for transfusion in non-splenectomized
patients is generally higher than in splenectomized
patients.
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Annex  I.
1.  Clinical  doubt
What is the purpose and recommended regimen of transfu-
sions in the treatment of beta-thalassemia major?
2.  Structured  questionI: Any transfusion regimen
C:. . ..  . ..  . ..  . ..  . .. . ..  . ..  . ..  . .. . .
O: When to indicate and what is the best transfusion regimen
oter.
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3.  Evidence  Search  Strategy
#1  – (beta-Thalas semia OR   Thalasse mia Major  OR  An emia,  Cooley*  OR 
Mediterranean Anemia* OR Hemoglobin F Disease) 
#2  -  (Blood  Transfusion* OR  Erythrocyte   Transfusion*  OR  Red  Blood  Cel l 
Transfusion*) 
#3 - “th era py/broad” [Filt er]) 
First search: = #1 AND #2 AND #3 = 49
(Beta-Thalassemia OR Thalassemia Major OR Anemia, Cooley* OR
Mediterranean Anemia* OR Hemoglobin F Disease) AND (Blood Trans-
fusion* OR Erythrocyte Transfusion* OR Red Blood Cell Transfusion*)
AND “therapy/broad” [Filter]) − 1150 studies found (17/06/2016)
4.  Works  found
Obtaining the evidence to be used to analyze the effectiveness
and dangers of the use of regular transfusion regimen in the
treatment of beta-thalassemia major employed the following
steps: preparing the clinical question, structuring the ques-
tion, search for evidence, critical evaluation and selection of
evidence, display of the results and recommendations.
The electronic databases consulted were Medline via
PubMed Central, Lilacs via BVS, EMBASE and CINAHL via
EBSCO. Manual searches were made after reviewing the ref-
erences (narrative or systematic), as well as of selected works.
The number of articles found after applying the inclusion
and exclusion criteria was 14.
5.  Criteria  for  inclusion  of  selected  works
The selection of studies, the evaluation of the titles and
abstracts obtained from the search strategy was conducted
by two independent and blinded researchers with skills in
preparing systematic reviews, strictly observing the estab-
lished inclusion and exclusion criteria described in the PICO
components. Works of potential relevance were separated.
5.1  According  to  the  study  design
Narrative reviews, case reports, case series and works pre-
senting preliminary results were, in principle, excluded from
the selection. Systematic reviews were used with the prin-
ciple of ﬁnding references that may have been overlooked
on employing the initial search strategy. Comparative obser-
vational studies, systematic reviews and narratives (in the
absence of systematic reviews) were included in these guide-
lines.
5.2  Language
Studies in Portuguese, English and Spanish were included.
5.3  According  to  the  publication
Only articles with available full texts were considered for the
critical evaluation.
6.  Critical  evaluation
When the selected article was deﬁned as a comparative study
(observational cohorts or non-randomized clinical trials), it
was subjected to an appropriate checklist of critical evalua-
tion, allowing the classiﬁcation of the study according to the
Newcastle Ottawa Scale17; for cohorts studies, scores ≥6 were
1 2 0 1 6;3  8(4):341–345
considered consistent and scores <6 were considered incon-
sistent.
7.  Presentation  of  results
Results with available evidence are deﬁned in a speciﬁc way,
wherever possible, in respect to the population, intervention,
outcomes, the presence or absence of beneﬁts and danger and
controversies.
8.  Recommendations
Recommendations were made by the authors of the review,
with the initial characteristic of the synthesis of evidence. The
evidence was then validated by all participating authors who
drafted the guidelines.
The degree of recommendation used was directly from
the power of the studies found according to the Oxford
classiﬁcation,18 and using the GRADE system.19
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